Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Emerg Infect Dis ; 29(2)2023 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-36564155

RESUMEN

We report intrafamilial transmission of monkeypox virus to all members of a family (father, mother, and 2 children). Case reports in young children have been extremely rare during the 2022 mpox outbreak. Their clinical signs were mild, and clinical diagnosis would be difficult without knowledge of the father's monkeypox virus infection.


Asunto(s)
Monkeypox virus , Mpox , Humanos , Niño , Preescolar , Monkeypox virus/genética , Mpox/diagnóstico , Mpox/epidemiología , Brotes de Enfermedades
2.
Eur J Clin Microbiol Infect Dis ; 38(11): 2087-2095, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31350634

RESUMEN

Enterococci are a significant cause of bacteraemia in healthcare-associated infections (HCAI), being resistant to cephalosporins and aminoglycosides often used in this setting. Our aim was to measure the rate of inefficient antimicrobial therapy and its impact on the outcome. We conducted a retrospective multicentre cohort study in 6 French institutions. Patients were identified through the laboratory's database, which extracted all positive blood cultures for Enterococcus spp. in 2016. Patients' data were gathered by reviewing hospital records. Efficient antimicrobial therapy was defined as any therapy containing at least one antibiotic compound with in vitro efficacy against Enterococcus spp.: amoxicillin, amoxicillin/clavulanic acid, piperacillin, piperacillin/tazobactam, imipenem, meropenem, vancomycin, daptomycin, linezolide, tigecycline. A short-term unfavourable outcome was defined as intensive care requirement and/or in-hospital death at least 48 h after positive blood culture. One hundred thirty-one patients were included; the main diagnosis was a urinary tract infection (46%) and a HCAI was observed in 54% of the cases. Four patients did not receive any antibiotic. Forty-three per cent of empirical antibiotic therapies and 17% of documented ones were inefficient for enterococcal bacteraemia. Sixty patients (46%) received amoxicillin as a documented therapy. Twenty-three per cent of the patients presented a short-term unfavourable outcome. Univariate and multivariate analyses showed that not receiving amoxicillin as a documented antibiotic therapy was associated with an unfavourable short-term outcome (p = 0.001). In conclusion, Enterococcal bacteraemia was associated with a high proportion of inefficient antimicrobial therapy. In multivariate analysis, amoxicillin use was associated with a better outcome.


Asunto(s)
Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Enterococcus/efectos de los fármacos , Anciano , Anciano de 80 o más Años , Programas de Optimización del Uso de los Antimicrobianos , Bacteriemia/microbiología , Femenino , Humanos , Masculino , Auditoría Médica , Estudios Retrospectivos , Resultado del Tratamiento
3.
Acta Derm Venereol ; 99(2): 170-174, 2019 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-30328468

RESUMEN

Bacteraemias are life-threatening conditions that require rapid care and antibiotherapy. Dermatological signs might help in deciding the most relevant treatment. The aim of this study was to determine the prevalence and clinical characteristics of cutaneous manifestations in hospitalized patients with bacteraemia. A cross-sectional study was conducted over a period of 1 year. All consecutive patients with a bacteraemia (except contaminations) were included and examined by a dermatologist within 48 h after positive blood cultures. Clinical (skin manifestations, diagnosis, origin of the bacteraemia) and laboratory (bacteria) data were recorded. In total, 401 bacteraemias in 375 patients were included for the final analysis. Thirty-nine cutaneous manifestations in 34 patients were noted, corresponding to a prevalence of 9%; 69% (n = 27) were considered primary cutaneous manifestations, 18% (n = 7) as secondary ones, 10% (n = 4) as contiguous, and 3% (n = 1) as undetermined. Gram-positive cocci, specifically Staphylococcus aureus and Streptococcus species, were the most frequent bacteria (n = 27, 69%).


Asunto(s)
Bacteriemia/epidemiología , Bacteriemia/microbiología , Enfermedades Cutáneas Bacterianas/epidemiología , Enfermedades Cutáneas Bacterianas/microbiología , Piel/microbiología , Adulto , Anciano , Anciano de 80 o más Años , Bacteriemia/diagnóstico , Niño , Estudios Transversales , Femenino , Francia/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , Enfermedades Cutáneas Bacterianas/diagnóstico , Infecciones Cutáneas Estafilocócicas/epidemiología , Infecciones Cutáneas Estafilocócicas/microbiología , Infecciones Estreptocócicas/epidemiología , Infecciones Estreptocócicas/microbiología , Factores de Tiempo , Adulto Joven
4.
Eur J Clin Microbiol Infect Dis ; 37(2): 325-331, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29164361

RESUMEN

Patients with bacteraemia constitute an useful population for an audit of antibiotic treatments. Empirical antibiotic therapy (EAT) and its reassessment must take into account clinical data and microbiological results. Our aim was to determine the impact of these sequential steps of the therapy on survival. This was a retrospective multicentre study which included patients admitted to emergency departments (ED) for whom blood cultures were positive over a 4-month period. Microbial results were compiled from the database of the laboratories. The relevant information was extracted from the computerized patient's chart. An efficient EAT was based on antibiotic susceptibility of the bacteria. An effective antibiotic reassessment (AR) was defined as any modification of the EAT. Unfavorable outcome was defined as death of the patient during in-hospital care. Three hospitals and two clinics took part in this study, 169 patients with bacteraemia being included. The diagnosis in ED was undetermined in 21 cases (12%), 35 patients (21%) required intensive care, and 23 died (14%). One hundred and thirty-six patients (80%) received an EAT, the latter being efficient in 107 cases (63%). An effective AR was performed in 116 cases (69%). In multivariate analysis, risks factors for death were: ongoing cancer AOR (adjusted odds ratio) 3.34, undetermined diagnosis in ED: AOR 9.34 and severe sepsis or shock: AOR 6.98. Effective AR was a protective factor: AOR 0.28 [0.09-0.81]. One third of bacteraemic patients in ED did not benefit from AR. Improvement of antimicrobial stewardship should be associated with a higher rate of survival.


Asunto(s)
Antibacterianos/uso terapéutico , Programas de Optimización del Uso de los Antimicrobianos/métodos , Bacteriemia/tratamiento farmacológico , Bacterias/efectos de los fármacos , Infección Hospitalaria/tratamiento farmacológico , Anciano , Bacteriemia/microbiología , Bacterias/aislamiento & purificación , Infección Hospitalaria/microbiología , Servicio de Urgencia en Hospital , Femenino , Hospitalización , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA